IGF2 and Hypoglycemia: Intravenously applied ERT using IGF2.GAA has been tested in a clinical trial with adult-onset Pompe patients, and this revealed a dose-dependent transient induction of hypoglycemia starting at a dose of 10 mg/kg during and/or within 2 h of the end of infusion.73